New drug combo aims to stop breast cancer return in High-Risk patients

NCT ID NCT05760612

Recruiting now Disease control Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated Apr 28, 2026 · Updated 29 times

Summary

This study tests whether a different combination of targeted drugs (trastuzumab plus neratinib) works better than the standard combo (trastuzumab plus pertuzumab) for women with a certain type of breast cancer (HER2-positive, hormone receptor-positive) who still have small amounts of cancer after initial treatment. About 300 women aged 18-70 will be randomly assigned to one of the two drug pairs. The main goal is to see which combination better prevents the cancer from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY STAGE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sun Yat-sen University Sun Yat-sen Memorial Hospital
RECRUITING

Guangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ADJUVANT TREATMENT AFTER TRASTUZUMAB EARLY STAGE BREAST CANCER HER2-POSITIVE BREAST CANCER NERATINI RCB CLASSIFICATION 1-2